Limitless Travel has announced a £6.5m Series A round led by venture capital firm Beringea, alongside Social Impact Enterprises, with participation from Adjuvo, Active Partners, Miroma Ventures, and existing investors including Nigel Wray.

IGX12 is a pioneering monoclonal antibody (mAb) with very strong and consistent pre-clinical results and the potential to revolutionize infertility treatment.

Origin Coffee announces a £3.1 million investment to support the growth of the business whilst continuing its commitment to improving sustainability within the industry.in the industry.

Financial proceeds will be used to advance Igyxos infertility breakthrough treatment towards its goal to transform lives of many facing fertility problems

French designer eyewear brand Bloobloom, which was founded in 2018 and has stores on London’s Carnaby Street and Marylebone High Street, is to open five additional London stores in 2023, following a new £5m round of seed funding.